Skip to main content

Table 2 Clinical improvement as assessed by ACR criteria

From: The human anti-IL-1β monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis

Assessor (time point) Response ACZ885 Placebo (n = 15) P value (10 mg/kg versus placebo)
   0.3 mg/kg (n = 6) 1.0 mg/kg (n = 6) 3.0 mg/kg (n = 6) 10 mg/kg (n = 19/20a)   
Blinded observer (day 43) ACR20 1 (17%) 0 (0%) 4 (67%) 6 (32%) 1 (7%) 0.085
  ACR50 0 (0%) 0 (0%) 1 (17%) 3 (16%) 0 (0%) 0.162
  ACR70 0 (0%) 0 (0%) 0 (0%) 2 (11%) 0 (0%) 0.305
Investigator (any time within 6 weeks of treatment start) ACR20 3 (50%) 2 (33%) 4 (67%) 10 (50%) 3 (20%) 0.070
  ACR50 0 (0%) 0 (0%) 2 (33%) 4 (20%) 0 (0%) 0.093
  ACR70 0 (0%) 0 (0%) 0 (0%) 3 (15%) 0 (0%) 0.174
  1. Shown are the number and percentage of patients achieving 20%, 50%, or 70% improvement in terms of American College of Rheumatology (ACR) criteria (ACR20, ACR50 and ACR70, respectively) at day 43 as assessed by a blinded observer and at any time point within 6 weeks of treatment start as assessed by the investigator. aNote that for one patient in the 10 mg/kg treatment group, the ACR criteria assessment by a blinded observer was not conducted at day 43.